ArticleFrontiers in immunology2026
The role of the NLRP3 inflammasome in hypertension-related chronic heart failure and its potential therapeutic targets.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypertension-induced pressure overload is a major driver of chronic heart failure (CHF) and is accompanied by persistent sterile inflammation. However, the upstream mechanisms linking mechanical stress to inflammasome activation across disease stages remain insufficiently defined. Objective: To characterize the stage-specific role of the extracellular ATP-P2X7-NLRP3 inflammasome axis in pressure overload-induced CHF and to assess its therapeutic potential. Methods: A transverse aortic constriction (TAC) mouse model was established and followed longitudinally using hemodynamic assessment and echocardiography. Extracellular ATP signaling, P2X7 activation, NLRP3 inflammasome priming and assembly, downstream effector responses, histologic remodeling, and inflammatory cell infiltration were evaluated across disease stages. Causality was tested using pharmacologic inhibition (P2X7 antagonism and the NLRP3 inhibitor MCC950) and genetic deletion of Nlrp3. Results: Pressure overload induced stage-dependent amplification of extracellular ATP-P2X7 signaling, accompanied by progressive activation of NLRP3 inflammasome pathways. These changes were associated with macrophage accumulation, worsening fibrosis, and declining cardiac function. Pharmacologic or genetic disruption of the ATP-P2X7-NLRP3 axis attenuated inflammasome signaling, reduced adverse remodeling, and improved cardiac structure and function. Conclusions: Extracellular ATP-P2X7 signaling is an upstream driver of NLRP3 inflammasome activation during pressure overload-induced CHF. The ATP-P2X7-NLRP3 axis may therefore represent a stage-informed and therapeutically actionable target for hypertension-related CHF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.